RESEARCH ARTICLE

Multisite verification of the accuracy of a multi-gene next generation sequencing panel for detection of mutations and copy number alterations in solid tumours

John Bartlett\textsuperscript{1,2,3} Yutaka Amemiya\textsuperscript{4}, Heleen Arts\textsuperscript{5,6}, Jane Bayani\textsuperscript{1}, Barry Eng\textsuperscript{5,6}, Daria Grafodatskaya\textsuperscript{6,6}, Suzanne Kamel Rei\textsuperscript{7,8,9}, Mathieu Lariviere\textsuperscript{9}, Bryan Lo\textsuperscript{10}, Rebecca McClure\textsuperscript{11}, Vinay Mittal\textsuperscript{9}, Bekim Sadikovic\textsuperscript{12,13}, Seth Sadis\textsuperscript{12}, Arun Seth\textsuperscript{12}, Jeff Smith\textsuperscript{9}, Xiao Zhang\textsuperscript{14}, Harriet Feilotter\textsuperscript{14,15}.

1 Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada, 2 Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, 3 Edinburgh Cancer Research Centre, Edinburgh, United Kingdom, 4 SRI Genomics Laboratory and Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, 5 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada, 6 Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, Ontario, Canada, 7 Department of Clinical Laboratory Genetics, The University Health Network, Toronto, Ontario, Canada, 8 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, 9 Thermo Fisher Scientific, South San Francisco, CA, United States of America, 10 Dept of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada, 11 Health Sciences North/Horizon Sudbury, Sudbury, Ontario, Canada, 12 Molecular Diagnostics Laboratory, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada, 13 Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada, 14 Department of Pathology and Molecular Medicine, Queen’s University, Kingston, Ontario, Canada, 15 Laboratory Genetics, Kingston Health Sciences Center, Kingston Ontario, Canada

\* Current address: Department of Pathology and Laboratory Medicine, Clinical Genomics Laboratory, Dalhousie University and IWK Health Centre, Halifax, Nova Scotia, Canada
\* Current address: Professor Emeritus at University of Toronto, Toronto, Ontario, Canada
\* hf4@queensu.ca

Abstract

Molecular variants including single nucleotide variants (SNVs), copy number variants (CNVs) and fusions can be detected in the clinical setting using deep targeted sequencing. These assays support low limits of detection using little genomic input material. They are gaining in popularity in clinical laboratories, where sample volumes are limited, and low variant allele fractions may be present. However, data on reproducibility between laboratories is limited. Using a ring study, we evaluated the performance of 7 Ontario laboratories using targeted sequencing panels. All laboratories analysed a series of control and clinical samples for SNVs/CNVs and gene fusions. High concordance was observed across laboratories for measured CNVs and SNVs. Over 97% of SNV calls in clinical samples were detected by all laboratories. Whilst only a single CNV was detected in the clinical samples tested, all laboratories were able to reproducibly report both the variant and copy number. Concordance for information derived from RNA was lower than observed for DNA, due largely to decreased quality metrics associated with the RNA components of the assay, suggesting that the RNA portions of comprehensive NGS assays may be more vulnerable to variations in approach.
and workflow. Overall the results of this study support the use of the OFA for targeted sequencing for testing of clinical samples and suggest specific internal quality metrics that can be reliable indicators of assay failure. While we believe this evidence can be interpreted to support deep targeted sequencing in general, additional studies should be performed to confirm this.

Introduction

The value of specific gene alterations to match individuals with cancer to molecularly targeted agents is now clear in many tumour types [1–18]. While current requirements for detection of somatic variants remain limited in specific jurisdictions such as Ontario, this is likely to change significantly as increased numbers of targeted therapies for both solid and hematologic tumours are approved by the FDA and Health Canada. Thus, it is expected that the need for broader mutation profiling for tumours will expand rapidly over the next several years.

Increasingly, broad genomic profiling, using whole genome or exome sequencing and whole transcriptome sequencing, is used in clinical trials of metastatic cancer to attempt to match patients to targeted therapeutics based on genomic features of their tumours [19–23]. Many of these trials highlight the complexity of delivering broad genomic analyses from small diagnostic samples in a timely fashion. To address this challenge a number of small and large targeted sequencing panels have been developed which cover key molecular alterations across multiple cancer types (e.g. MSK-IMPACT, Foundation One, TruSight series, Oncomine series). Among these, the Oncomine Focus (OFA) and Oncomine Comprehensive v3 (OCAv3) assays have been adopted in a number of clinical diagnostic laboratories globally. Notably, the OCAv3 is the assay of choice in the on-going Adult and Pediatric NCI- Molecular Analysis for Therapy Choice (MATCH) programs (NCT02465060/ NCT03155620) [24, 25], to allocate metastatic patients to novel targeted therapeutics. In Canada, OCAv3 is also being used by the CAPTUR, OCTANE [26, 27] and the Exactis Innovation [28] programs, to stratify patients with advanced cancer for treatment based on molecular alternations. The OFA is a smaller and more economical version of the OCAv3, and, like OCAv3, has the advantage of being appropriate for small amounts of DNA/RNA extracted from formalin fixed paraffin embedded (FFPE) diagnostic samples. Both OCAv3 and OFA can be readily adopted in routine clinical settings combining deep coverage of key genes using next generation sequencing methodology and a curated informatics reporting pipeline. Critical, however, to the implementation and subsequent clinical validation of any assay in the routine clinical setting is the ability to rely on accurate and reproducible results. In order to assess the accuracy and reproducibility of the OFA for detection of mutations, copy number alterations and fusions, we performed a ring study that included two research and five clinical molecular diagnostic laboratories in Ontario and compared results using a small series of solid tumour and control specimens.

Materials and methods

Study design and samples

The study was designed to assess the performance of the OFA across research and clinical laboratories in Ontario. Ethics approval was obtained from the Queen’s University Research Ethics Board (Study PATH-161-16). The study was divided into two phases. In phase 1, participating
centers were provided with extracted nucleic acids from 3 control DNA (Horizon Quantitative Multiplex Reference Standard, Horizon KRAS Gene-Specific Multiplex Reference Standard and Horizon EGFR Gene-Specific Multiplex Reference Standard) and 1 control RNA (Horizon HD784) cell lines, as well as 9 DNA samples and 11 RNA samples extracted from anonymized solid tumours (Table 1). Nucleic acids for use in phase 1 were extracted at the Kingston Health Sciences Center. For phase 2, 6-μm sections from 8 of the tumours used in phase 1 were placed onto unbaked glass slides. A parallel H&E slide was examined by a pathologist, and marked to identify the tumour area. Images of the marked slides for each tumour were made available to each centre. Two slides were sent to each participating center. Each center received non-consecutive slides (i.e. slide 1 and slide 8, slide 2 and slide 9, etc) to minimize the probability of tumour heterogeneity being a major factor confounding the results. For phase 2, each center performed RNA and DNA extraction individually and used the extracted material as input to the OFA.

Participating centers

The following centers participated in the study: Kingston Health Sciences Center (Feilotter), Sunnybrook Health Sciences Centre (Seth), Ontario Institute for Cancer Research (Bartlett), Princess Margaret Hospital/UHN (Kamel Reid), Ottawa Hospital (Lo), London Health Sciences Centre (Sadikovic), Health Science North (McClure). Each center was provided a code letter (A-G) to anonymize results. All centers except Laboratory F used the OFA assay; Laboratory F used the OCAv3 assay. The centers running the OFA assay used either a Ion Torrent PGM sequencer and a 318 chip, or the Ion Torrent S5XL sequencer and a 520 chip. Laboratory F used an Ion Torrent S5XL sequencer and a 540 chip (Thermo Fisher Scientific, Waltham, MA, USA).

Table 1. List of samples used in the study.

| Sample | Tissue    | Phase 1 | Phase 2 |
|--------|-----------|---------|---------|
|        | DNA | RNA | DNA | RNA | Slides |
| 1      | NSCLC | X   | X   | X   |
| 2      | Colon | X   | X   | X   |
| 3      | Melanoma | X | X | X |
| 4      | NSCLC | X | X | X |
| 5      | Melanoma | X | X |
| 6      | Colon | X | X | X |
| 7      | NSCLC | X | X | X |
| 8      | NSCLC | X | X | X |
| 9      | Melanoma | X | X | X |
| 10     | Colon | X |
| 11     | Melanoma | X |
| DNA Std Ref | Cell line | X |
| KRAS DNA Ref | Cell line | X |
| EGFR DNA Ref | Cell line | X |
| RNA Std Ref | Cell line | X |

NSCLC: Non small cell lung cancer; DNA Std Ref: Horizon Quantitative Multiplex Reference Standard; KRAS DNA Ref: Horizon KRAS Gene-Specific Multiplex Reference Standard; EGFR DNA Ref: Horizon EGFR Gene-Specific Multiplex Reference Standard; RNA Std Ref: Horizon HD784.

https://doi.org/10.1371/journal.pone.0258188.t001
DNA/RNA extraction
For phase 1, DNA was extracted in the Kingston laboratory, using the RecoverAll™ RNA/DNA extraction kit for FFPE tissue (Thermo Fisher Scientific, Waltham, MA, USA). DNA was provided to all sites at 2ng/μl, and participating laboratories were instructed to use 5 μl (10 ng) of each DNA solution for library preparation and sequencing. RNA samples were provided at 5ng/μl, and laboratories were instructed to use 2 μl (10 ng) of each for library construction and sequencing. For phase 2, each participating laboratory carried out their own extractions using methods that had been previously validated in their laboratories.

Sequencing
Sequencing was performed following the instructions provided with the Oncomine Focus (Laboratories A, B, C, D, E and G) or Comprehensive (Laboratory F) Assay Library Preparation User Guide. The OFA covers hotspot mutations in 35 genes, CNV detection in 19 genes and gene fusions related to 23 genes (https://www.thermofisher.com/uk/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-oncology/oncomine-focus-assay.html) and covers all recognized targets for gene targeted therapies. The OCAv3 assays includes these genes and others including: full exon coverage of 48 genes, hotspot mutation detection of 87 genes, CNV detection of 43 genes and fusions for 51 genes. Libraries were sequenced following instructions provided in the Ion Hi-Q Chef Kit, Ion 520–530 Kit Chef or Ion 540 Kit Chef reference guide. Instructions for standardized naming of samples from each site were provided, ensuring consistency across the study.

Data generation and analysis
Sequencing runs were originally analyzed using Torrent Suite Software (TSS) versions 5.0–5.4 (depending on the timing of when runs were completed) to generate BAM files, which were uploaded to the Ion Reporter (IR) server. After completion of the study, all runs were re-analyzed using default IR Oncomine workflows in IR v5.10. DNA quality metrics were analyzed using a TSS coverage analysis plugin, and RNA quality metrics were investigated using attributes from the BAM file as well as the IR fusion workflow metrics. Minimum standards were specified according to standards provided with the OFA and OCAv3 assays. For OFA, at the time of the study, a minimum of 300,000 mapped reads for DNA and 5,000 mapped reads for RNA was required to pass quality control. More recently, the minimum number of mapped reads for RNA was changed to 50,000, and both of these metrics were used in analysis. For OCAv3, a minimum of 3,000,000 reads for DNA and 500,000 reads for RNA was required. At the time of the study, the minimum fragment length for OFA for DNA was 100, and for RNA 75 bases. More recently, this has been changed to 75 for DNA and 60 for RNA, and both metrics were considered in analysis. For OCAv3, the minimum length were set at 80 and 60 bases for DNA and RNA respectively. The minimum percent uniformity was set at 80% for both OFA and OCAv3. Variant summary files were created as VCF files. Three different types of variants (SNV/indel, copy number variant and fusion genes) were assessed using default calling settings.

Results
Quality metrics
Quality metrics, including read length, mapped reads (DNA & RNA) and uniformity of base coverage (DNA), are reported in Tables 2–6 for phase 1 and Tables 7–11 for phase 2. Samples not meeting the minimum standards set out in the Methods are flagged.
Phase 1

One sample (the DNA standard, Laboratory E) failed for technical reasons (not sequencing related) and results for this sample were not reported. No sample failed either the original or the updated read length metric (Table 2), Two samples (Samples 2 and 5) failed both the minimum mapped read requirement (Table 3) and the uniformity percentage for DNA (Table 4) in Laboratory G. Twelve samples (including 2 reference samples) failed the original RNA read length metric (Table 5), including 6 from Laboratory B, although this was reduced to 5 failed samples using the newer minimum read length requirement of 60 bases. Three samples failed the OCAv3 mapped read value (Table 6). For OFA, the RNA reference failed the original mapped read requirement in Laboratory E. Using the updated metric of minimum of 50,000 mapped RNA reads, substantially higher numbers of failures were seen, in particular from laboratories B, and D.

Phase 2

In phase 2, no samples failed for the DNA read length values (Table 7). One sample failed for number of DNA mapped reads for OFA, and 3 samples failed OCAv3 for this metric (Table 8). The same samples, plus one additional OCAv3 sample failed the uniformity metric (Table 9). For RNA, laboratories B, D and F saw most samples fail using the original read length metric, with fewer failures (mostly in laboratory B) using the new metric (Table 10). However, using the newer metric for required minimum number of RNA mapped reads, laboratories B and D saw multiple failures across samples, while Laboratory F was unsuccessful with the RNA runs for all samples using OCAv3.

Data from flagged samples was not considered in the following analyses unless otherwise specified.

Control DNA/RNA samples

Table 12 shows the data from the three DNA control samples (Standard 1: Quantitative Multiplex Reference Standard FFPE; Standard 2: EGFR Gene-Specific Multiplex Reference Standard
5% FFPE; Standard 3: KRAS Gene-Specific Multiplex Reference Standard FFPE, Horizon Discovery, Waterbeach, UK). All variants were regarded as detected if expected variant allele fractions (VAFs) were greater than or equal to 5%. All variants above 5% were detected by all laboratories, apart from a single failed run (laboratory E) for DNA standard 1. Results using the RNA reference control (Standard 4: HD796 (formerly HD 784) reference from Horizon Discovery) are shown in Table 13. Five of the laboratories detected the majority of fusions, although laboratories E and F did not detect any fusions.

**Variant calls from clinical specimens**

**Hotspot SNV/indel calls.** The 8 solid tumour samples were assessed for the presence of variant calls. Each sample had previously been assayed using a clinically validated Ion AmpliSeq Cancer HotSpot Panel v2 assay (Thermo Fisher Scientific, Waltham, MA, USA). Results

The number of mapped reads are provided for each sample in phase 1. The minimum acceptable mapped reads for OFA is 300,000, and for OCAv3 is 3,000,000. ND: no data-sample failed this run for technical reasons. Values in bold italics are flagged because they do not meet minimum requirements.

![Table 3. Phase 1 DNA mapped read values.](https://doi.org/10.1371/journal.pone.0258188.t003)

| Panel     | OFA | OFA | OFA | OFA | OFA | OCAv3 | OFA |
|-----------|-----|-----|-----|-----|-----|-------|-----|
| Sample/lab | A   | B   | C   | D   | E   | F     | G   |
| 1         | 817.88k | 1.14M | 1.00M | 635.22k | 1.26M | 9.07M | 427.08k |
| 2         | 865.60k | 793.22k | 1.11M | 516.94k | 879.42k | 8.45M | **181.60k** |
| 3         | 975.25k | 1.05M | 839.76k | 449.65k | 745.41k | 5.71M | 514.47k |
| 4         | 870.91k | 1.02M | 1.22M | 733.76k | 1.64M | 7.45M | 466.94k |
| 5         | 889.95k | 1.04M | 1.09M | 515.54k | 989.02k | 6.37M | 154.82k |
| 6         | 937.83k | 1.12M | 815.43k | 531.01k | 1.33M | 8.69M | 424.43k |
| 7         | 909.77k | 861.01k | 1.13M | 642.19k | 1.62M | 10.02M | 624.47k |
| 8         | 930.70k | 1.02M | 1.01M | 508.22k | 1.73M | 5.51M | 759.83k |
| 9         | 891.46k | 1.33M | 863.18k | 473.78k | 744.14k | 8.62M | 383.61k |

**DNA Stnd Ref** 968.70k 1.16M 501.39k 693.20k ND 5.12M 697.74k

**KRAS DNA** 935.71k 822.90k 540.92k 432.01k 882.78k 7.05M 732.38k

**EGFR DNA** 878.53k 1.00M 849.01k 525.64k 684.11k 4.79M 816.08k

![Table 4. Phase 1 DNA uniformity values.](https://doi.org/10.1371/journal.pone.0258188.t004)

| PANEL     | OFA | OFA | OFA | OFA | OFA | OCAv3 | OFA |
|-----------|-----|-----|-----|-----|-----|-------|-----|
| SAMPLE/LAB | A   | B   | C   | D   | E   | F     | G   |
| 1         | 99.08 | 97.47 | 98.38 | 92.8 | 98.67 | 91.14 | 96.37 |
| 2         | 99.05 | 99.48 | 96.92 | 96.99 | 98.26 | 96.6 | **0.17** |
| 3         | 96.78 | 98.23 | 97.83 | 94.84 | 97.27 | 87.7 | 97.82 |
| 4         | 98.94 | 97.76 | 97.6 | 95.8 | 97.54 | 95.17 | 98.2 |
| 5         | 98.89 | 99.41 | 95.74 | 96.06 | 97.96 | 93.84 | **0.41** |
| 6         | 98.98 | 98.16 | 97.17 | 95.87 | 98.13 | 96.15 | 99.07 |
| 7         | 99.1 | 96.13 | 98.21 | 95.66 | 98.09 | 94.7 | 99.09 |
| 8         | 99.05 | 97.49 | 98.19 | 94.83 | 97.97 | 94.46 | 99.09 |
| 9         | 98.87 | 97.81 | 96.54 | 98.39 | 98.58 | 81.66 | 99.77 |

**DNA Stnd Ref** 98.27 | 96.15 | 97.13 | 96.68 | ND | 97.34 | 98.89

**KRAS DNA** 97.63 | 92.96 | 96.21 | 96.33 | 94.94 | 96.18 | 98.24

**EGFR DNA** 98.89 | 96.86 | 96.81 | 97.04 | 97.67 | 97.47 | 98.56

Uniformity is provided as a percentage for each sample in phase 1. The minimum acceptable uniformity percentage for both assays is 80%. ND: No data- sample failed this run for technical reasons. Values in bold italics are flagged because they do not meet minimum requirements.
from the clinically validated assay were accepted as the “true” results for each sample, and results from the ring study were measured against these expected calls.

In phases 1 and 2, a total of 11 different gain of function hotspot variants were expected (Table 14) across 11 samples run in the 7 sequencing laboratories. For this analysis, data from all runs were included to allow investigation of which quality metrics might be critical for variant calling. Overall 143/147 potential variants were successfully called (97.3%). VAFs for all of the positively called variants were highly concordant between all laboratories for both phases (Table 14). Three calls were missed by LaboratoryG due to two phase 1 samples that failed to

| PANEL | OFA  | OFA  | OFA  | OFA  | OFA  | OFA  | OCAv3 | OFA  |
|-------|------|------|------|------|------|------|-------|------|
| SAMPLE/LAB | A    | B    | C    | D    | E    | F    | G     |      |
| 1     | 91   | 81   | 96   | 83   | 90   | 71   | 98    |      |
| 2     | 97   | 86   | 96   | 91   | 86   | 83   | 118   |      |
| 3     | 101  | 93   | 99   | 93   | 97   | 53   | 106   |      |
| 4     | 96   | 87   | 99   | 85   | 94   | 93   | 70    | 118  |
| 5     | 97   | 89   | 98   | 94   | 93   | 70   | 118   |      |
| 6     | 99   | 64   | 95   | 92   | 98   | 79   | 104   |      |
| 7     | 85   | 66   | 94   | 77   | 94   | 84   | 98    |      |
| 8     | 87   | 85   | 90   | 84   | 87   | 90   | 94    |      |
| 9     | 98   | 68   | 98   | 96   | 98   | 91   | 105   |      |
| 10    | 87   | 79   | 89   | 51   | 86   | 80   | 97    |      |
| 11    | 96   | 53   | 101  | 88   | 94   | 45   | 101   |      |
| RNA Ref Stnd | 97   | 82   | 97   | 84   | 96   | 77   | 102   |      |

Read length is provided for each sample in phase 1. The minimum acceptable read length for RNA for OFA is 80 bases (later changed to 60 bases), and for OCAv3 is 60 bases. Values in bold italics are flagged because they do not meet the original minimum requirements. Values in bold italics underlined did not meet the newer requirements for OFA.

https://doi.org/10.1371/journal.pone.0258188.t005

In phases 1 and 2, a total of 11 different gain of function hotspot variants were expected (Table 14) across 11 samples run in the 7 sequencing laboratories. For this analysis, data from all runs were included to allow investigation of which quality metrics might be critical for variant calling. Overall 143/147 potential variants were successfully called (97.3%). VAFs for all of the positively called variants were highly concordant between all laboratories for both phases (Table 14). Three calls were missed by LaboratoryG due to two phase 1 samples that failed to

| PANEL | OFA  | OFA  | OFA  | OFA  | OFA  | OFA  | OCAv3 | OFA  |
|-------|------|------|------|------|------|------|-------|------|
| SAMPLE/LAB | A    | B    | C    | D    | E    | F    | G     |      |
| 1     | 137.70k | 71.86k | 148.53k | 55.09k | 121.82k | 991.89k | 172.18k |      |
| 2     | 183.97k | 88.86k | 147.96k | 51.64k | 132.93k | 877.35k | 113.32k |      |
| 3     | 193.29k | 140.72k | 252.44k | 16.63k | 270.57k | 367.04k | 116.39k |      |
| 4     | 209.62k | 144.92k | 240.52k | 34.21k | 189.05k | 2.27M   | 142.59k |      |
| 5     | 153.64k | 232.99k | 305.74k | 74.35k | 399.78k | 630.37k | 207.67k |      |
| 6     | 180.33k | 33.36k  | 201.73k | 46.63k | 225.27k | 2.05M   | 80.29k  |      |
| 7     | 144.36k | 11.95k  | 221.35k | 12.44k | 323.45k | 1.22M   | 172.18k |      |
| 8     | 177.19k | 130.94k | 174.96k | 46.86k | 305.90k | 572.87k | 101.18k |      |
| 9     | 195.71k | 51.93k  | 260.33k | 82.77k | 377.21k | 1.85M   | 279.10k |      |
| 10    | 88.68k  | 62.02k  | 32.97k  | 2.61k  | 230.66k | 644.67k | 8.75k   |      |
| 11    | 225.34k | 5.97k   | 263.52k | 44.34k | 230.66k | 7.21k   | 99.24k  |      |
| RNA Ref Stnd | 180.73k | 83.53k | 230.05k | 35.11k | 2.16k  | 88.99k  | 142.45k |      |

Total mapped reads is provided for each sample in phase 1. The minimum number of reads for OFA is 5,000, (later changed to 50,000) and for OCAv3 is 500,000. Values in bold italics are flagged because they do not meet the original minimum requirements. Values in bold italics underlined did not meet the newer quality requirements for OFA.

https://doi.org/10.1371/journal.pone.0258188.t006
meet the minimum number of reads and required uniformity, suggesting a problem with the quality of the sequencing for those samples. The final missed call from Laboratory F was for a phase 2 sample, where again the number of mapped reads and uniformity were below acceptable metrics.

**Copy number variant calls.** Copy number variant calls are automatically assessed using the median of the absolute values of all pairwise differences (MAPD) in the Ion Reporter Software. Table 15 shows the MAPD values for each sample across each laboratory for phases 1 and 2. Generally, copy number can be assessed if the MAPD value remains below 0.5. In phase 1, Samples 1 and 9 had values >0.5 from Laboratory F. In phase 2, Sample 4 had an MAPD value greater than 0.5 for Laboratory B, and all samples from Laboratory F with the exception of sample 7 had MAPD values > 0.5. From the clinical samples, copy number gain of the MYC locus was consistently identified in Sample 4, with copy gain estimates ranging from 6.76 to 11.6 across both phases (Table 16).

**RNA fusions.** A MET exon 14 skipping call was made in 3 samples in 2 labs (Samples 2, 6 and 9 in both phase 1 and 2 in Lab A and Sample 9 in both phase 1 and 2 in Lab G. All fusion calls were below 1% of total mapped RNA reads. No materials remain for orthogonal validation of the calls.

### Table 7. Phase 2 DNA read length values.

| PANEL | OFA | OFA | OFA | OFA | OFA | OCAv3 | OFA |
|-------|-----|-----|-----|-----|-----|-------|-----|
| SAMPLE/LAB | A   | B   | C   | D   | E   | F     | G   |
| 1     | 111 | 111 | 114 | 110 | 111 | 109   | 113 |
| 2     | 118 | 118 | 117 | 112 | 115 | 81    | 116 |
| 3     | 113 | 114 | 115 | 110 | 111 | 93    | 116 |
| 4     | 112 | 106 | 112 | 107 | 105 | 87    | 115 |
| 6     | 114 | 119 | 115 | 110 | 117 | 97    | 114 |
| 7     | 110 | 114 | 114 | 107 | 110 | 111   | 113 |
| 8     | 111 | 112 | 115 | 108 | 111 | 109   | 113 |
| 9     | 114 | 116 | 116 | 110 | 116 | 91    | 116 |

Read lengths are provided for each sample in phase 2. The minimum acceptable read length for OFA is 100 base pairs (later changed to 75 base pairs), and for OCAv3 is 75 base pairs.

https://doi.org/10.1371/journal.pone.0258188.t007

### Table 8. Phase 2 DNA mapped read values.

| PANEL | OFA | OFA | OFA | OFA | OFA | OCAv3 | OFA |
|-------|-----|-----|-----|-----|-----|-------|-----|
| SAMPLE/LAB | A   | B   | C   | D   | E   | F     | G   |
| 1     | 1.27M | 1.61M | 1.56M | 1.54M | 1.06M | 8.35M | 864.97k |
| 2     | 1.47M | 1.31M | 1.82M | 1.63M | 1.15M | 1.43M | 1.12M |
| 3     | 1.35M | 1.49M | 1.38M | 1.63M | 803.23k | 2.24M | 716.22k |
| 4     | 1.09M | 184.06k | 1.55M | 772.39k | 1.12M | 1.82M | 3.41M |
| 6     | 1.23M | 1.60M | 1.45M | 1.28M | 1.38M | 4.83M | 1.04M |
| 7     | 1.36M | 1.58M | 1.43M | 1.06M | 845.89k | 6.85M | 673.43k |
| 8     | 1.29M | 1.55M | 1.43M | 1.73M | 961.44k | 6.32M | 2.11M |
| 9     | 1.36M | 1.47M | 718.58k | 360.23k | 1.36M | 3.01M | 1.29M |

The number of mapped reads are provided for each sample in phase 2. The minimum acceptable mapped reads for OFA is 300,000, and for OCAv3 is 3,000,000. Values in bold italics are flagged because they do not meet minimum requirements.

https://doi.org/10.1371/journal.pone.0258188.t008


Discussion

Targeted next generation sequencing assays, also referred to as massively parallel sequencing assays, to identify variants in tumours have become standard practice in many clinical laboratories. In Ontario, laboratories currently offer a variety of such panels, including the commonly used Ion AmpliSeq Cancer HotSpot Panel v2 assay (Thermo Fisher Scientific) as well as the TruSight panels (Illumina). In the early days of next generation sequencing, most laboratories relied on panels that detected single nucleotide variants and small insertions or deletions. However, currently more laboratories are assessing panels designed to interrogate high-level copy number changes, as well as the expression of fusion events in an effort to conserve precious sample volumes and curb the costs and the time associated with sequential multiple testing.

We engaged in a ring study including five clinical and two research laboratories across Ontario to assess the parameters of one such assay, the Oncomine Focus Assay (Thermo Fisher Scientific). The rationale was to determine the potential strengths and weaknesses of the assay and to provide important data that could subsequently assist laboratories to validate the assay in house. Ultimately, one of the clinical laboratories involved opted to utilize a larger panel (OCAv3), which limited some of the comparisons that could be made.

Table 9. Phase 2 DNA uniformity values.

| PANEL | OFA | OFA | OFA | OFA | OFA | OCAv3 | OFA |
|-------|-----|-----|-----|-----|-----|-------|-----|
| SAMPLE/LAB | A   | B   | C   | D   | E   | F     | G   |
| 1     | 97.53 | 98.19 | 90.9 | 91.54 | 99.59 | 97 | 98.01 |
| 2     | 97.93 | 97.03 | 91.62 | 98.1 | 97.96 | 53.85 | 98.49 |
| 3     | 97.26 | 93.19 | 95.56 | 96.36 | 91.8 | 68.45 | 93.83 |
| 4     | 96.78 | 69.22 | 97.54 | 94.29 | 91.15 | 61.36 | 97.44 |
| 5     | 96.97 | 97.69 | 96.49 | 98.1 | 96.19 | 86.03 | 97.73 |
| 6     | 96.94 | 90.53 | 90.45 | 93.83 |       |       |     |
| 7     | 97.54 | 97.66 | 96.92 | 96.12 | 85.93 | 96.65 | 95.2  |
| 8     | 98.56 | 98.35 | 92.14 | 91.08 | 98.77 | 96.71 | 97.26 |
| 9     | 96.04 | 96.12 | 94.1 | 96.87 | 90.33 | 68.03 | 90.7  |

Uniformity is provided as a percentage for each sample in phase 2. The minimum acceptable uniformity percentage for both assays is 80%. Values in bold italics are flagged because they do not meet minimum requirements.

https://doi.org/10.1371/journal.pone.0258188.t009

Table 10. Phase 2 RNA read length values.

| PANEL | OFA | OFA | OFA | OFA | OFA | OCAv3 | OFA |
|-------|-----|-----|-----|-----|-----|-------|-----|
| SAMPLE/LAB | A   | B   | C   | D   | E   | F     | G   |
| 1     | 90 | 54 | 92 | 75 | 88 | 34 | 95 |
| 2     | 100 | 62 | 101 | 72 | 99 | 48 | 92 |
| 3     | 100 | 53 | 101 | 50 | 91 | 63 | 100 |
| 4     | 98 | 52 | 95 | 89 | 82 | 72 | 98 |
| 6     | 98 | 43 | 100 | 81 | 98 | 37 | 101 |
| 7     | 95 | 83 | 94 | 77 | 89 | 50 | 93 |
| 8     | 91 | 53 | 91 | 65 | 92 | 58 | 92 |
| 9     | 100 | 48 | 102 | 64 | 98 | 97 | 102 |

Read length is provided for each sample in phase 2. The minimum acceptable read length for RNA for OFA is 80 bases (later changed to 60 bases), and for OCAv3 is 60 bases. Values in bold italics are flagged because they do not meet the original minimum requirements. Values in underlined bold italics do not meet the updated requirements.

https://doi.org/10.1371/journal.pone.0258188.t010

Discussion

Targeted next generation sequencing assays, also referred to as massively parallel sequencing assays, to identify variants in tumours have become standard practice in many clinical laboratories. In Ontario, laboratories currently offer a variety of such panels, including the commonly used Ion AmpliSeq Cancer HotSpot Panel v2 assay (Thermo Fisher Scientific) as well as the TruSight panels (Illumina). In the early days of next generation sequencing, most laboratories relied on panels that detected single nucleotide variants and small insertions or deletions. However, currently more laboratories are assessing panels designed to interrogate high-level copy number changes, as well as the expression of fusion events in an effort to conserve precious sample volumes and curb the costs and the time associated with sequential multiple testing.

We engaged in a ring study including five clinical and two research laboratories across Ontario to assess the parameters of one such assay, the Oncomine Focus Assay (Thermo Fisher Scientific). The rationale was to determine the potential strengths and weaknesses of the assay and to provide important data that could subsequently assist laboratories to validate the assay in house. Ultimately, one of the clinical laboratories involved opted to utilize a larger panel (OCAv3), which limited some of the comparisons that could be made.

Table 9. Phase 2 DNA uniformity values.

| PANEL | OFA | OFA | OFA | OFA | OFA | OCAv3 | OFA |
|-------|-----|-----|-----|-----|-----|-------|-----|
| SAMPLE/LAB | A   | B   | C   | D   | E   | F     | G   |
| 1     | 97.53 | 98.19 | 90.9 | 91.54 | 99.59 | 97 | 98.01 |
| 2     | 97.93 | 97.03 | 91.62 | 98.1 | 97.96 | 53.85 | 98.49 |
| 3     | 97.26 | 93.19 | 95.56 | 96.36 | 91.8 | 68.45 | 93.83 |
| 4     | 96.78 | 69.22 | 97.54 | 94.29 | 91.15 | 61.36 | 97.44 |
| 5     | 96.97 | 97.69 | 96.49 | 98.1 | 96.19 | 86.03 | 97.73 |
| 6     | 96.94 | 90.53 | 90.45 | 93.83 |       |       |     |
| 7     | 97.54 | 97.66 | 96.92 | 96.12 | 85.93 | 96.65 | 95.2  |
| 8     | 98.56 | 98.35 | 92.14 | 91.08 | 98.77 | 96.71 | 97.26 |
| 9     | 96.04 | 96.12 | 94.1 | 96.87 | 90.33 | 68.03 | 90.7  |

Uniformity is provided as a percentage for each sample in phase 2. The minimum acceptable uniformity percentage for both assays is 80%. Values in bold italics are flagged because they do not meet minimum requirements.

https://doi.org/10.1371/journal.pone.0258188.t009

Table 10. Phase 2 RNA read length values.

| PANEL | OFA | OFA | OFA | OFA | OFA | OCAv3 | OFA |
|-------|-----|-----|-----|-----|-----|-------|-----|
| SAMPLE/LAB | A   | B   | C   | D   | E   | F     | G   |
| 1     | 90 | 54 | 92 | 75 | 88 | 34 | 95 |
| 2     | 100 | 62 | 101 | 72 | 99 | 48 | 92 |
| 3     | 100 | 53 | 101 | 50 | 91 | 63 | 100 |
| 4     | 98 | 52 | 95 | 89 | 82 | 72 | 98 |
| 6     | 98 | 43 | 100 | 81 | 98 | 37 | 101 |
| 7     | 95 | 83 | 94 | 77 | 89 | 50 | 93 |
| 8     | 91 | 53 | 91 | 65 | 92 | 58 | 92 |
| 9     | 100 | 48 | 102 | 64 | 98 | 97 | 102 |

Read length is provided for each sample in phase 2. The minimum acceptable read length for RNA for OFA is 80 bases (later changed to 60 bases), and for OCAv3 is 60 bases. Values in bold italics are flagged because they do not meet the original minimum requirements. Values in underlined bold italics do not meet the updated requirements.

https://doi.org/10.1371/journal.pone.0258188.t010
It was clear that the assays in all 7 laboratories were performing at a level sufficient to reliably detect all DNA variants from control cell lines at 5% VAF or greater. Although we did not do a formal study of limit of detection, we can determine that with the mean depths achieved in these studies (\(>1200\) reads per amplicon), both assays can reliably detect SNVs and indels present in at least 5% of the molecules interrogated. Likewise, using control materials to investigate the ability of the assays to identify fusions by way of input total RNA, laboratories

| PARTICIPATING LABS |
|---------------------|
| A | B | C | D | E | F | G |
generally were able to detect the fusions. Laboratories unable to detect fusions in control materials were either using the OCAv3 assay and likely were limited by the amount of RNA provided, or showed failed quality metrics for both mean read length and total mapped RNA.

Table 13. Detection of fusions from the RNA control material across the ring study laboratories.

| Fusion Gene A | Fusion Gene B | PARTICIPATING LABS- Absolute counts (%) |
|---------------|---------------|----------------------------------------|
| A             | B             | C           | D             | E             | F             | G             |
| EML4 (13)     | ALK (20)      | 5870(3.25)  | 59(0.07)      | 4622(2.01)    | 228(0.65)     | NC            | NC            | 2984(2.09)    |
| CCDC6 (1)     | RET (12)      | 8094(4.48)  | 53(0.06)      | 1945(0.85)    | 237(0.68)     | NC            | NC            | 4334(3.04)    |
| SLC34A2 (4)   | ROS1 (32)     | 17789(9.84) | 4523(5.41)    | 27677(12.03)  | 9183(26.16)   | NC            | NC            | 22353(15.69)  |
| SLC34A2 (4)   | ROS1 (34)     | 11170(6.02) | 73(0.09)      | 1361(0.59)    | 244(0.69)     | NC            | NC            | 1195(0.84)    |

Numbers are provided as absolute counts, and as fraction of total mapped RNA reads. NC = not called.

https://doi.org/10.1371/journal.pone.0258188.t013

Table 14. Variant allele fractions for the gain of function variants detected by the ring study laboratories across Phase 1 and Phase 2 for the clinical specimens.

| SAMPLE | GENE | VARIANT | ID    | A       | B       | C       | D       | E       | F       | G       |
|--------|------|---------|-------|---------|---------|---------|---------|---------|---------|---------|
| 1      | KRAS | p.G12V  | COSM20| 16/14   | 17/11   | 15/14   | 17/13   | 17/13   | 15/11   | 16/19   |
| 2      | KRAS | p.G12V  | COSM20| 37/39   | 38/41   | 38/39   | 39/39   | 39/39   | 37/26   | -/19    |
| 2      | MET  | p.T1010I| COSM70| 49/48   | 48/49   | 46/49   | 47/49   | 49/46   | 44/-    | -/49    |
| 4      | KRAS | p.G12D  | COSM52| 48/40   | 51/34   | 49/43   | 49/37   | 48/40   | 48/39   | 45/42   |
| 5      | NRAS | p.Q61K  | COSM58| 48/na   | 46/na   | 45/na   | 46/na   | 47/na   | 46/na   | -/na    |
| 6      | BRAF | p.V600E | COSM47| 42/47   | 42/44   | 42/47   | 39/42   | 39/44   | 38/44   | 42/42   |
| 6      | PIK3CA| p.H1047R| COSM75| 26/29   | 26/29   | 28/30   | 28/27   | 31/28   | 27/30   | 25/32   |
| 7      | KRAS | p.G12C  | COSM51| 15/23   | 16/17   | 14/23   | 13/17   | 16/20   | 17/15   | 15/27   |
| 8      | EGFR | p.I747_<delT751> | COSM12369| 34/30 | 34/21 | 30/30 | 33/29 | 33/30 | 30/31 | 30/30 |
| 8      | PIK3CA| p.C420R | COSM75| 32/25   | 31/22   | 31/28   | 32/27   | 35/31   | 31/27   | 34/28   |
| 9      | BRAF | p.V600E | COSM47| 60/69   | 61/66   | 62/65   | 61/67   | 60/65   | 57/57   | 62/67   |

na: Sample was not assessed in Phase 2.

https://doi.org/10.1371/journal.pone.0258188.t014

Table 15. Median of the absolute values of pairwise differences across labs.

| SAMPLE | LABS (Phase 1/Phase 2) |
|--------|------------------------|
| A      | B | C  | D  | E  | F  | G  |
| 1      | 0.27/0.31 | 0.26/0.33 | 0.37/0.37 | 0.28/0.32 | 0.25/0.27 | 0.51/0.57 | 0.28/0.29 |
| 2      | 0.19/0.25 | 0.19/0.22 | 0.27/0.33 | 0.26/0.18 | 0.21/0.2 | 0.39/1.04 | 0.21/0.22 |
| 3      | 0.29/0.26 | 0.24/0.26 | 0.26/0.25 | 0.27/0.25 | 0.27/0.35 | 0.49/0.86 | 0.27/0.26 |
| 4      | 0.2/0.27 | 0.23/0.53 | 0.25/0.27 | 0.27/0.34 | 0.23/0.28 | 0.48/0.87 | 0.25/0.28 |
| 5      | 0.21 | 0.16 | 0.25 | 0.22 | 0.2 | 0.41 | 0.26 |
| 6      | 0.2/0.4 | 0.24/0.29 | 0.31/0.28 | 0.29/0.24 | 0.2/0.24 | 0.48/0.65 | 0.26/0.3 |
| 7      | 0.21/0.33 | 0.31/0.34 | 0.26/0.32 | 0.28/0.28 | 0.22/0.37 | 0.45/0.47 | 0.23/0.35 |
| 8      | 0.27/0.3 | 0.27/0.3 | 0.34/0.42 | 0.3/0.3 | 0.3/0.25 | 0.4/0.54 | 0.27/0.33 |
| 9      | 0.23/0.28 | 0.2/0.24 | 0.27/0.3 | 0.24/0.23 | 0.22/0.28 | 0.62/0.89 | 0.26/0.32 |

Samples for which MAPD values were >0.5 are underlined.

https://doi.org/10.1371/journal.pone.0258188.t015
reads for the control sample. The relationship of the low quality metrics with the lack of fusion detection confirms that the quality metrics are critical components of the assay that must be tracked and used to guide interpretation. Among the laboratories that successfully detected the fusions, we noted variability in the relative number of fusion molecules detected between laboratories. This variability persisted even when visualizing the fusion results as proportion of total mapped reads. The reason for this is not clear, but does suggest that the RNA metrics for these assays require careful scrutiny, and that clinical laboratories should ensure that they independently determine minimum standards for fusion calling, which could well be somewhat different for different fusion molecules of interest.

Using clinical formalin fixed paraffin embedded specimens, clinically relevant hotspot calls were consistent (97% of clinically relevant calls were made using orthogonal data as a standard) across all assays and on all samples tested, with highly similar VAFs, with 3 exceptions. The missed calls highlighted the importance of the quality metrics associated with each sample, as all calls that were missed were from samples where the quality indicators of mapped read numbers and uniformity would have flagged the sample as substandard quality. Clearly, the assay quality metrics highlight samples where clinically relevant calls might be missed, and should be appropriately tracked and used as indicators to repeat assays, where possible. Barring that, the presence of out of range quality metrics, in particular mapped reads and uniformity, should flag a sample to be reported as inconclusive rather than negative. However, given the extremely high accuracy of detecting actionable mutations in repeat analyses across 7 laboratories using either previously extracted or locally extracted DNA, we conclude that this assay satisfies important criteria relating to accuracy and reproducibility across multiple testing laboratories for mutation detection.

Identification of copy number variants is becoming an increasingly useful technique, as large-scale or gene-level genomic amplifications or deletions are being associated with drug response or prognosis. In this study, only a single sample was shown to have an amplification of the MYC locus, and the calls from all of the laboratories were consistent and reproducible. Perhaps more strikingly, the numerical copy number estimates for all of the known gain of function CNV areas represented on the OFA assay were highly concordant between the participating centres. Again, given the high consistency, and reproducibility of both calls (gain/loss/no change) and copy number estimates, we conclude this to be a highly reproducible CNV assessment platform. We are limited in our ability to comment broadly on accuracy for CNV detection because a) the gains observed were not orthogonally validated (being non-actionable at this time) and b) there being only 1 gain in the samples assessed.

Table 16. Copy number gain for MYC detected in Sample 4 in Phase 1 and Phase 2 across labs.

| Lab | Phase-I | Phase-II |
|-----|---------|----------|
| A   | 9.54    | 9.83     |
| B   | 10.1    | 6.76*    |
| C   | 9.61    | 8.67     |
| D   | 10.7    | 6.89     |
| E   | 10.17   | 8.81     |
| F   | 11.6    | 7.74*    |
| G   | 10.39   | 10.72    |

Assessment for copy number changes was limited to genes present on the OFA assay. The asterisk denotes samples where the MAPD value was >0.5.

https://doi.org/10.1371/journal.pone.0258188.t016

reads for the control sample. The relationship of the low quality metrics with the lack of fusion detection confirms that the quality metrics are critical components of the assay that must be tracked and used to guide interpretation. Among the laboratories that successfully detected the fusions, we noted variability in the relative number of fusion molecules detected between laboratories. This variability persisted even when visualizing the fusion results as proportion of total mapped reads. The reason for this is not clear, but does suggest that the RNA metrics for these assays require careful scrutiny, and that clinical laboratories should ensure that they independently determine minimum standards for fusion calling, which could well be somewhat different for different fusion molecules of interest.

Using clinical formalin fixed paraffin embedded specimens, clinically relevant hotspot calls were consistent (97% of clinically relevant calls were made using orthogonal data as a standard) across all assays and on all samples tested, with highly similar VAFs, with 3 exceptions. The missed calls highlighted the importance of the quality metrics associated with each sample, as all calls that were missed were from samples where the quality indicators of mapped read numbers and uniformity would have flagged the sample as substandard quality. Clearly, the assay quality metrics highlight samples where clinically relevant calls might be missed, and should be appropriately tracked and used as indicators to repeat assays, where possible. Barring that, the presence of out of range quality metrics, in particular mapped reads and uniformity, should flag a sample to be reported as inconclusive rather than negative. However, given the extremely high accuracy of detecting actionable mutations in repeat analyses across 7 laboratories using either previously extracted or locally extracted DNA, we conclude that this assay satisfies important criteria relating to accuracy and reproducibility across multiple testing laboratories for mutation detection.

Identification of copy number variants is becoming an increasingly useful technique, as large-scale or gene-level genomic amplifications or deletions are being associated with drug response or prognosis. In this study, only a single sample was shown to have an amplification of the MYC locus, and the calls from all of the laboratories were consistent and reproducible. Perhaps more strikingly, the numerical copy number estimates for all of the known gain of function CNV areas represented on the OFA assay were highly concordant between the participating centres. Again, given the high consistency, and reproducibility of both calls (gain/loss/no change) and copy number estimates, we conclude this to be a highly reproducible CNV assessment platform. We are limited in our ability to comment broadly on accuracy for CNV detection because a) the gains observed were not orthogonally validated (being non-actionable at this time) and b) there being only 1 gain in the samples assessed.

Table 16. Copy number gain for MYC detected in Sample 4 in Phase 1 and Phase 2 across labs.

| Lab | Phase-I | Phase-II |
|-----|---------|----------|
| A   | 9.54    | 9.83     |
| B   | 10.1    | 6.76*    |
| C   | 9.61    | 8.67     |
| D   | 10.7    | 6.89     |
| E   | 10.17   | 8.81     |
| F   | 11.6    | 7.74*    |
| G   | 10.39   | 10.72    |

Assessment for copy number changes was limited to genes present on the OFA assay. The asterisk denotes samples where the MAPD value was >0.5.

https://doi.org/10.1371/journal.pone.0258188.t016
The RNA findings from the clinical specimens were less robust. The smaller number of assays performed and the wider quality metrics make interpretation of this part of the assay more challenging. However, although we did not have available material to confirm the presence of MET exon 14 skipping events in the 4 samples where that event was detected, we were able to determine that the samples in which the skipping event was called were unlikely to carry such a biomarker. Of the 4 clinical specimens with a suggested MET exon14 skipping event, two were melanoma samples, one of which also carried a driver NRAS mutation, one was a colorectal cancer and the last was a lung cancer sample with a KRAS driver mutation. These tumours would be unlikely to harbour a MET exon 14 skipping driver mutation, suggesting that these calls could be false positives. Indeed, more recent developments with the OFA/OCAv3 assays suggests that calling this particular RNA-based biomarker requires careful calibration of the assay, ensuring that the skipping event is called with a minimum of 1000 reads [29]. The remaining fusion calls that were identified in three additional phase 2 samples are also likely to be false positives, given they were not detected by most laboratories, and never in the matched phase 1 samples. The variability seen in the RNA portion of the assays highlights again that this part of the assay is more vulnerable to laboratory handling and workflow. Of interest the quality metrics for the RNA results were not markedly different between phase I (where pre-extracted mRNA was shipped to laboratories) and phase II (where laboratories extracted RNA locally). This suggests that the quality issues are not related to degradation of samples during shipping. Clearly, the metrics that accompany the assays are relevant for all clinical laboratories to ensure high quality results, but the RNA aspects of the assays likely require independent assessment of lab-specific metrics to ensure consistency and to limit false calls.

Overall we demonstrate that the OFA is a highly accurate and reproducible platform, in both the clinical diagnostic and research setting, for the detection of SNVs and CNVs using low input FFPE derived DNA. We have limited data about OCAv3, given that only a single laboratory used this assay, and results from this laboratory were likely compromised by the limited amount of material that could be shared and the 2X higher input amounts needed for that assay. Since only one participating laboratory used the OCAv3 assay we cannot extend our broader findings relating to OFA to OCAv3, or indeed other assays. The major limitation of this study is the small number of samples used, which was due to the difficulty of identifying clinical specimens with sufficient material to be shared cross multiple laboratories. Despite the limited number of samples, however, the data do provide important guidance about quality metrics that should be monitored for use of both DNA and RNA as input materials for next generation sequencing assays. Overall, this study further strengthens the case for using panel-based testing for small samples with limited amounts of available diagnostic material and provides some insights into the use of quality metrics to flag compromised samples with a high risk of false negative results. It also provide important insights into the importance of standardized protocols, training and robust clinical validation prior to the use of these assays in the clinical setting. Specifically, important insights from this study suggest that a) the quality metrics tracked in the study for both DNA and RNA components are critical elements of the analytic process and should be part of any standardized approach to assessing the assays, and b) that the RNA component appears more variable, suggesting that clinical validation for each fusion requiring detection might be considered independently. As panel-based targeted sequencing becomes more widely available, studies like the one presented here may form an invaluable source of data to inform quality assurance and assessment approaches to diagnostic targeted sequencing assays.

The use of panels such as OFA or OCA in the clinical setting for patients means that even patients with very small amounts of tumour material may be able to access molecular testing
to guide their clinical management. In Ontario, testing for predictive biomarkers including \textit{EGFR} for lung adenocarcinoma, \textit{BRAF} in malignant melanoma and \textit{KRAS} and \textit{BRAF} in metastatic colorectal cancer supports the use of targeted therapies for these patients. Assays such as those investigated in this study will continue to provide this critical information to patients as these indications continue to expand. The onus on the laboratories continues to be to ensure that the metrics guiding the use of these assays are well understood.

\textbf{Acknowledgments}

We acknowledge the technical support provided by Tyler Kirwan, Amanda Marolt and Zachary Castonguay, from the Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, Ontario, Canada.

\textbf{Author Contributions}

\textbf{Conceptualization:} John Bartlett, Harriet Feilotter.

\textbf{Data curation:} Xiao Zhang.

\textbf{Formal analysis:} John Bartlett, Jane Bayani, Vinay Mittal, Harriet Feilotter.

\textbf{Investigation:} Yutaka Amemiya, Heleen Arts, Jane Bayani, Barry Eng, Daria Grafodatskaya, Suzanne Kamel Reid, Bryan Lo, Rebecca McClure, Bekim Sadikovic, Arun Seth, Xiao Zhang, Harriet Feilotter.

\textbf{Methodology:} John Bartlett, Jane Bayani, Daria Grafodatskaya, Xiao Zhang, Harriet Feilotter.

\textbf{Project administration:} John Bartlett, Harriet Feilotter.

\textbf{Resources:} Mathieu Lariviere, Seth Sadis, Jeff Smith.

\textbf{Supervision:} Xiao Zhang, Harriet Feilotter.

\textbf{Writing – original draft:} John Bartlett, Harriet Feilotter.

\textbf{Writing – review & editing:} John Bartlett, Yutaka Amemiya, Heleen Arts, Jane Bayani, Barry Eng, Daria Grafodatskaya, Suzanne Kamel Reid, Mathieu Lariviere, Bryan Lo, Rebecca McClure, Vinay Mittal, Bekim Sadikovic, Seth Sadis, Arun Seth, Jeff Smith, Xiao Zhang, Harriet Feilotter.

\textbf{References}

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129–2139 https://doi.org/10.1056/NEJMoa040938 PMID: 15118073

2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659–1672

3. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23:8081–92 https://doi.org/10.1200/JCO.2005.02.7078 PMID: 16204011

4. Hirsch FR, Varella-Garcia M, Bunn PA Jr., Franklin WA, Dziadzio szko R, Thatcher N, et al.: Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2006, 24:5034–42 https://doi.org/10.1200/JCO.2006.06.3958 PMID: 17075123

5. Robert NJ, Eiermann W, Pienkowski T, Crown J, Martin M, Pawlicki M, et al.: BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up. ASCO Meeting Abstracts. 2007, 25:19647
6. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008, 359:1757–1765 https://doi.org/10.1056/NEJMoa0804385 PMID: 18946061

7. Kancha RK, von Bubnoff N, Peschel C, Duyster J.: Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy. Clinical Cancer Research. 2009, 15:460–7 https://doi.org/10.1158/1078-0432.CCR-08-1757 PMID: 19147750

8. De RW, Jonker DJ, Di NF, Sartore-Bianchi A, Tu D, Siena S, et al.: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. Jama. 2010, 304:1812–20 https://doi.org/10.1001/jama.2010.1535 PMID: 20978259

9. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP: A landscape of driver mutations in melanoma. Cell 2012, 150:251–263 https://doi.org/10.1016/j.cell.2012.06.024 PMID: 22817889

10. Lovly CM, Dahanik KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE 2012, 7 https://doi.org/10.1371/journal.pone.0035309 PMID: 22536370

11. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors guideline from the college of American pathologists. Int J Thorac Oncol 2013, 8:823–859

12. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamashita M, Nishihara R: Microsatellite instability and braf mutation testing in colorectal cancer prognostic. J Natl Cancer Inst 2013, 105:1151–1156 https://doi.org/10.1093/jnci/djt173 PMID: 23878352

13. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C: Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013, 19:4532–4540 https://doi.org/10.1158/1078-0432.CCR-13-0657 PMID: 23833300

14. Kaderbhai CG, Boidot R, Belljens F, Chevrier S, Arnold L, Favier L: Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer. Oncotarget 2016, 7 e20523–e20523 https://doi.org/10.18632/oncotarget.8391 PMID: 27027238

15. The AARC Project GENIE Consortium, Abstract AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov 2017, 7:818–831 https://doi.org/10.1158/2159-8290.CD-17-0151 PMID: 28572459

16. Wala J, Bandopadhayay P, Greenwald N, O’Rourke R, Sharpe T, Stewart C: Genome-wide detection of structural variants and indels by local assembly. BioRxiv 2017,105080

17. Lee YJ, Kim D, Kim HS, Na K, Lee JY, Nam EJ, et al.: Integrating a next generation sequencing panel into clinical practice for ovarian cancer. Yonsei Med J 2019, 60:914–923 https://doi.org/10.3349/ymj.2019.60.10.914 PMID: 31538426

18. Shin H, Sa JK, Bae JS, Koo H, Jin S, Cho HJ, et al.: Clinical targeted next-generation sequencing panels for detection of somatic variants in gliomas. Cancer Res Treat 2020, 52:41–50 https://doi.org/10.4143/crt.2019.036 PMID: 31096737

19. Tsimeridou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, et al.: Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol 2019, 12:145 https://doi.org/10.1186/s13045-019-0835-1 PMID: 31886787

20. Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, et al.: Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: an exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget 2020, 11:2906–2918 https://doi.org/10.18632/oncotarget.27658 PMID: 32774771

21. Walsh N, Andrieu C, O’Donovan P, Quinn C, Maguire A, Furney SJ, et al.: Whole exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer. Br J Cancer 2020, https://doi.org/10.1038/s41416-020-0999-z PMID: 32713940

22. Réda M, Richard C, Bertaut A, Norgret J, Collot T, Furnet JD, et al.: Implementation and use of whole exome sequencing for metastatic solid cancer. EBioMedicine 2020, 51:102624. https://doi.org/10.1016/j.ebiom.2019.10.007 PMID: 32188106
25. Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, et al: Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia 2015, 17:385–99 https://doi.org/10.1016/j.neo.2015.03.004 PMID: 25925381

26. Malone ER, Saleh RR, Yu C, Ahmed L, Pugh T, Torchia J, et al: OCTANE (Ontario-wide cancer targeted nucleic acid evaluation): a platform for intraprovincial, national, and international clinical data-sharing. Curr Oncol 2019, 26:e618–e623 https://doi.org/10.3747/co.26.5235 PMID: 31708655

27. Spence T, Stickle N, Yu C, Chow H, Feilotter H, Lo B, et al: Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study. Curr Oncol. 2019, 26:e717–e732 https://doi.org/10.3747/co.26.5379 PMID: 31896942

28. Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, et al: Analysis of the genomic landscape in ALK+NSCLC patients identifies novel aberrations associated with clinical outcomes. Mol Cancer Ther 2019, 18:1628–1636 https://doi.org/10.1158/1535-7163.MCT-19-0105 PMID: 31243098

29. Oliveira DM, Mirante T, Mignonna C, Scrima M, Migliozzi S, Rocco G, et al: Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. Oncotarget 2018, 9:22749–22768 https://doi.org/10.18632/oncotarget.25229 PMID: 29854313